Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Shigesawa T, Maehara O, Suda G, Natsuizaka M, Kimura M, Shimazaki T, Yamamoto K, Yamada R, Kitagataya T, Nakamura A, Suzuki K, Ohara M, Kawagishi N, Umemura M, Nakai M, Sho T, Morikawa K, Ogawa K, Ohnishi S, Sugiyama M, Mizokami M, Takeda H, Sakamoto N.
Shigesawa T, et al. Among authors: mizokami m.
Carcinogenesis. 2021 Feb 11;42(1):58-69. doi: 10.1093/carcin/bgaa049.
Carcinogenesis. 2021.
PMID: 32449510